English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, April 24, 2019
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
エーザイ、「攻めのIT経営銘柄2019」に選定
Eisai Selected as Competitive ICT Strategy Company for 2019
Monday, April 8, 2019
エーザイ、新規線維芽細胞増殖因子(FGF)受容体選択的チロシンキナーゼ阻害剤「E7090」が厚生労働省の「先駆け審査指定制度」において対象品目に指定
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
エーザイ、「チョコラBB(R)スパークリング キウイ&レモン味」新発売
Friday, April 5, 2019
エーザイ、シリーズ初の医薬部外品「トラベルミン(R)サポート」新発売
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Friday, March 29, 2019
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575